Education
About Us
Working with TipRanks
Follow Us
Humana Inc (HUM)
NYSE:HUM
HUM Analyst Ratings
Moderate Buy
5 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HUM Stock 12 Month Forecast
Average Price Target
$293.13
▲(3.97% Upside)
| Highest Price Target$348.00 | Average Price Target$293.13 | Lowest Price Target$256.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Cantor Fitzgerald
Reiterated
04/08/25
Guggenheim
Initiated
04/08/25
Wells Fargo
Reiterated
04/07/25
Bernstein
Reiterated
03/24/25
Morgan Stanley
Reiterated
03/21/25
Truist Financial
Reiterated
02/21/25
Barclays
Reiterated
02/21/25
J.P. Morgan
Reiterated
02/18/25
Leerink Partners
Reiterated
02/12/25
Bank of America Securities
$308
Hold
9.24%
Upside
Reiterated
02/12/25
Humana's Stable MLR Projections Amid Margin Pressures and Regulatory Challenges Support Hold RatingWe ticked down 2025E EPS for the guide, maintained 2026E, and rolled out 2027E. We reiterate Neutral given the uncertainties. 100bps to MA margins is nearly $6 of EPS From 2019 to now, insurance segment pre-tax margins have steadily decreased from 3.6% to 1.1%. Our forecasts are below consensus on insurance pre-tax margins, as the Street expects offsets to the lost Stars to be more impactful in 2026, increasing afterwards. We estimate that if MA margins expand 100bps, it would be a close to $6/share tailwind to 2025E EPS. In PDP, an equivalent increase to margin would add 25c to 2025E EPS (Exhibit 5). Star ratings and the ongoing court case are catalysts which could boost margins, especially in the MA segment.
TD Cowen
$268
Hold
-4.95%
Downside
Reiterated
02/12/25
Humana's Financial Outlook: Balancing Strategic Investments and Uncertainties Justifies 'Hold' Rating
Piper Sandler
$288
Hold
2.15%
Upside
Reiterated
02/12/25
Piper Sandler Keeps Their Hold Rating on Humana (HUM)
Mizuho Securities
$305
Buy
8.18%
Upside
Reiterated
02/11/25
Humana's Strong Financial Performance and Strategic Investments Justify Buy RatingWe expect today's call to focus on 2025 guidance, the expectations for a larger than originally expected decline in MA membership, and the potential recovery in MA margins. Overall, we view this as a positive and believe continued execution is key for the stock.
RBC Capital
$283
Buy
0.37%
Upside
Reiterated
02/11/25
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Humana (NYSE: HUM) and Staar Surgical (NASDAQ: STAA)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Cantor Fitzgerald
Reiterated
04/08/25
Guggenheim
Initiated
04/08/25
Wells Fargo
Reiterated
04/07/25
Bernstein
Reiterated
03/24/25
Morgan Stanley
Reiterated
03/21/25
Truist Financial
Reiterated
02/21/25
Barclays
Reiterated
02/21/25
J.P. Morgan
Reiterated
02/18/25
Leerink Partners
Reiterated
02/12/25
Bank of America Securities
$308
Hold
9.24%
Upside
Reiterated
02/12/25
Humana's Stable MLR Projections Amid Margin Pressures and Regulatory Challenges Support Hold RatingWe ticked down 2025E EPS for the guide, maintained 2026E, and rolled out 2027E. We reiterate Neutral given the uncertainties. 100bps to MA margins is nearly $6 of EPS From 2019 to now, insurance segment pre-tax margins have steadily decreased from 3.6% to 1.1%. Our forecasts are below consensus on insurance pre-tax margins, as the Street expects offsets to the lost Stars to be more impactful in 2026, increasing afterwards. We estimate that if MA margins expand 100bps, it would be a close to $6/share tailwind to 2025E EPS. In PDP, an equivalent increase to margin would add 25c to 2025E EPS (Exhibit 5). Star ratings and the ongoing court case are catalysts which could boost margins, especially in the MA segment.
TD Cowen
$268
Hold
-4.95%
Downside
Reiterated
02/12/25
Humana's Financial Outlook: Balancing Strategic Investments and Uncertainties Justifies 'Hold' Rating
Piper Sandler
$288
Hold
2.15%
Upside
Reiterated
02/12/25
Piper Sandler Keeps Their Hold Rating on Humana (HUM)
Mizuho Securities
$305
Buy
8.18%
Upside
Reiterated
02/11/25
Humana's Strong Financial Performance and Strategic Investments Justify Buy RatingWe expect today's call to focus on 2025 guidance, the expectations for a larger than originally expected decline in MA membership, and the potential recovery in MA margins. Overall, we view this as a positive and believe continued execution is key for the stock.
RBC Capital
$283
Buy
0.37%
Upside
Reiterated
02/11/25
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Humana (NYSE: HUM) and Staar Surgical (NASDAQ: STAA)
Best Analysts Covering Humana
Which Analyst Should I Follow If I Want to Buy HUM and Sell After:
1 Month
xxx
Success Rate
23/36 ratings generated profit
Average Return
+1.18%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.89% of your transactions generating a profit, with an average return of +1.18% per trade.
3 Months
xxx
Success Rate
25/36 ratings generated profit
Average Return
+2.29%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.44% of your transactions generating a profit, with an average return of +2.29% per trade.
1 Year
Success Rate
22/36 ratings generated profit
Average Return
+4.04%
reiterated a buy rating 5 months ago
Copying Michael Wiederhorn's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +4.04% per trade.
2 Years
xxx
Success Rate
27/36 ratings generated profit
Average Return
+12.04%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +12.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HUM Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
4
0
0
0
0
Buy
12
5
7
9
9
Hold
36
17
25
18
16
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
22
32
27
25
Each month's total comprises the sum of three months' worth of ratings.
HUM Financial Forecast
HUM Stock Forecast FAQ
What is HUM’s average 12-month price target, according to analysts?
Based on analyst ratings, Humana Inc’s 12-month average price target is $293.13.
What is HUM’s upside potential, based on the analysts’ average price target?
Humana Inc has 3.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HUM a Buy, Sell or Hold?
Humana Inc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 10 hold ratings and 0 sell ratings.
What is Humana Inc’s price target?
The average price target for Humana Inc is $293.13. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $348.00 ,the lowest forecast is $256.00. The average price target represents 3.97% Increase from the current price of $281.95.
The highest analyst price target is $348.00 ,the lowest forecast is $256.00. The average price target represents 3.97% Increase from the current price of $281.95.
What do analysts say about Humana Inc?
Humana Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of HUM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.